Creating a new treatment to block harmful immune responses in blood diseases
Development of a first-in-class complement inhibitor for treating complement-mediated hematologic diseases
This study is working on a new treatment to help people with blood disorders like PNH and AIHA by creating special therapies that can stop the body from destroying red blood cells too quickly, aiming to offer better options than what’s currently available.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10990215 on NIH RePORTER |
What this research studies
This research focuses on developing a novel complement inhibitor aimed at treating hematologic diseases like paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). The approach involves creating and testing new nanobody-based therapies that can effectively inhibit excessive complement activation, which leads to the destruction of red blood cells. Patients may benefit from this research as it seeks to provide a more effective treatment option than currently available therapies. The research will involve both the development of these inhibitors and testing their effectiveness in preclinical models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) or autoimmune hemolytic anemia (AIHA).
Not a fit: Patients with other types of anemia or blood disorders not related to complement activation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective treatment for patients suffering from complement-mediated blood diseases.
How similar studies have performed: Previous research has shown promise in developing complement inhibitors, but this approach aims to create a first-in-class treatment that has not yet been tested.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Lin, Feng C — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Lin, Feng C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.